87S.F - Roivant Sciences Ltd.

Roivant Sciences Ltd.

50 Broadway
7th Floor
London SW1H 0DB
United Kingdom
44 20 7400 3347
https://roivant.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 863

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Matthew Gline	CEO & Director	1.45M	N/A	1984
Dr. Eric Venker M.D., Pharm.D.	Pres & COO	981.38k	N/A	1987
Dr. Mayukh Sukhatme M.D.	Pres & Chief Investment Officer	910.19k	N/A	1976
Mr. Richard Pulik	Chief Financial Officer	N/A	N/A	1980
Ms. Rakhi Kumar	Chief Accounting Officer	N/A	N/A	1980
Dr. Huafeng Xu Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Mr. Josh Chen	Gen. Counsel	N/A	N/A	N/A
Ms. Kelly Graff	Head of People	N/A	N/A	N/A
Ms. Marianne L. Romeo	Head of Global Transactions & Risk Management	N/A	N/A	1968
Mr. Alex Gasner	Exec. VP of Roivant Health	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Roivant Sciences Ltd. focuses on discovery, development, and commercialization of medicines. It develops transformative medicines by building technologies and developing talent in creative ways, leveraging its platform to launch Vants – nimble and focuses biopharmaceutical and health technology companies. The company was founded in 2014 and is based in London, the United Kingdom.

Corporate governance

Roivant Sciences Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.